LINKS TO HLRCC RESEARCH - RCC (Renal Cell Carcinoma)


Potential genetic anticipation in hereditary leiomyomatosis-renal cell cancer (HLRCC) Wong MH, Tan CS, Lee SC, Yong Y, Ooi AS, Ngeow J, Tan MH, 2014

This article describes that the average age of onset of kidney cancer decreases with each generation.


Kidney cancer - UK incidence statistics

Also has world-wide information.

Evaluation and screening for hereditary renal cell cancers W. Marston Linehan, 2013

Confirms the recommendations of the HLRCC Handbook.


NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma, With Molecular Targeted Therapy Hudes et al.,2011

This provides a comprehensive overview of drug treatments and rationales for RCC.

Reduced Expression of Fumarate Hydratase in Clear Cell Renal Cancer Mediates HIF-2α Accumulation and Promotes Migration and Invasion Sunil Sudarshan, Karthigayan Shanmugasundaram, Susan L. Naylor, Shu Lin, Carolina B. Livi, Christine F. O'Neill, Dipen J. Parekh, I-Tien Yeh, Lu-Zhe Sun, and Karen Block, 2011

This article describes the effect of reduced fumarase activity on RCC metastasis and wound healing.

High-Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma and Metastatic Melanoma: Still the Standard Janice P. Dutcher, 2011

Interleukin 2 (IL-2, Proleukin) can produce a complete cure for metastatic renal cell cancer was described in 2002.

Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma Gardie B, Remenieras A, Kattygnarath D, Bombled J, Lefèvre S, Perrier-Trudova V, Rustin P, Barrois M, Slama A, Avril MF, Bessis D, Caron O, Caux F, Collignon P, Coupier I, Cremin C, Dollfus H, Dugast C, Escudier B, Faivre L, Field M, Gilbert-Dussardier B, Janin N, Leport Y, Leroux D, Lipsker D, Malthieu F, McGilliwray B, Maugard C, Méjean A, Mortemousque I, Plessis G, Poppe B, Pruvost-Balland C, Rooker S, Roume J, Soufir N, Steinraths M, Tan MH, Théodore C, Thomas L, Vabres P, Van Glabeke E, Meric JB, Verkarre V, Lenoir G, Joulin V, Deveaux S, Cusin V, Feunteun J, Teh BT, Bressac-de Paillerets B, Richard S; French National Cancer Institute "Inherited predisposition to kidney cancer",2011

The link is to the abstract with the full text available on subscription. A new study showing that type 2 papillary renal cell carcinoma may be the only symptom of HLRCC in some individuals. This study also identified and characterized 21 novel FH mutations.

Familial and inherited renal cancers Barrett and Choyke, Cambridge Books Online © Cambridge University Press, 2011

The link is to the abstract with the full text available on subscription. This describes RCC in BHD, VHL and HLRCC, is well illustrated and highlights the need for RCC in HLRCC to be treated with radical surgery.

Renal cell cancer among African Americans: an epidemiologic review Loren Lipworth, Robert E Tarone and Joseph K McLaughlin, 2011

This open access article has a comprehensive analysis of statistics of possible causes of RCC with 127 references.

CASE REPORTS : Spontaneous Regression of Metastatic Type II Papillary Renal Cell Carcinoma Nicholas E. Power, Stephen A. Poon, Clarisse Mazzola, Jonathan L. Silberstein, Robert J. Motzer, Ana M. Molina, Snehal G. Patel, Jonathan A. Coleman, 2011

Paper on spontaneous regression of mRCC.

Thermal ablation of small renal masses: intermediate outcomes from a Canadian center Erdeljan P, Dhar M, Wignall G, Kozak R, Pautler SE., 2011 CT-guided percutaneous cryoablation of renal masses in selected patients C, Nicolai N, Lanocita R, Morosi C, Catanzaro M, Civelli E, Torelli T, Stagni S, Piva L, Frigerio LF, Marchianò A, Salvioni R., 2011

These 2 links are to the abstracts, subscription required for full articles. They describe good results from cryoablation (CA) and radio frequency ablation (RFA). These are nephron sparing procedures that destroy renal tissue in situ rather than by surgical removal. However these techniques are not recommended for HLRCCtumors - consult HLRCC Handbook.


The renal cell carcinoma market: Votrient to challenge Sutent’s lead Lorena Tonarelli, 2010

Discussion of different drugs for treating RCC.

Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer Staehler M, Haseke N, Stadler T, Nuhn P, Roosen A, Stief CG, and Wilkowski R., 2010

This paper describes a break-through in the treatment of metastatic RCC by sensitizing the cancer cells with sunitinib in parallel with radiation therapy.

Therapies for advanced kidney cancer 2010

Written for the Kidney Cancer Association and has description of different drugs for treating advanced RCC.


Genetic Basis of Bilateral Renal Cancer: Implications for Evaluation and Management W. Marston Linehan, 2009

General discussion of bilateral tumors for a number of genetic conditions including HLRCC.

Genetic Basis for Kidney Cancer: Opportunity for Disease-Specific Approaches to Therapy Elizabeth Cartwright Pfaffenroth, and W. Marston Linehan, 2009

Targeted treatments for kidney cancers.

Hereditary leiomyomatosis and renal cell carcinoma: very early diagnosis of renal cancer in a paediatric patient Ismail Alrashdi, Samantha Levine, Joan Paterson, Rohit Saxena, Soonie R. Patel, Sarita Depani, Darren R. Hargrave, Kathy Pritchard-Jones, Shirley V. Hodgson, 2009

The link is to the article abstract. The full article PDF is available on subscription. Although RCC is usually found in adults this article describes an 11-year old boy who was diagnosed with RCC on his first HLRCC screening. Useful discussion on screening guidelines.


HIF and fumarate hydratase in renal cancer S Sudarshan, W M Linehan and L Neckers,2007

ull detailed technical article covering the suggested causes of RCC in VHL as well as HLRCC.

The Morphologic Spectrum of Kidney Tumors in Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) Syndrome Maria J. Merino,Carlos Torres-Cabala,Peter Pinto, and William Marston Linehan, 2007

The link is to the article abstract. The full article PDF is available on subscription. Technical discussion of tumor types associated with HLRCC.

Renal Follow-up of HLRCC Syndrome Patients Kujala M, Aittomäki K, Ruutu M, 2007

This has a recommendation for 6-monthly RCC follow-up screening with MRI contrast.


Hereditary form of RCC best treated aggressively, study shows Urology Times Daily Meeting Report Dr. Linehan 2005

The author recommends surgical therapy early in the course of treatment of HLRCC patients instead of wait-and-see management.

Copyright © 2004 - 2018 Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)Family Alliance
c/o VHL Alliance, 1208 VFW Parkway // Suite 303, Boston, MA 02132
+1-617-277-5667 ext. 3 or +1-800-767-4845, ext. 3

Last modified: December 13 2017 22:29:33.